Helus Pharma™ Announces US$50 Million Underwritten Offering

Helus Pharma, a pharmaceutical company focused on developing innovative treatments for mental health, has announced a $50 million underwritten offering of its common shares. This move is expected to bolster its pipeline of novel serotonergic agonists, potentially accelerating its drug development and commercialization efforts. Given the growing demand for effective mental health treatments, this funding could significantly impact the company's ability to bring new therapies to market, highlighting its role in addressing a critical health need.